bluebird bio (BLUE) AML Case is Unlikely Driven By Lentiglobin, Here's Why - Morgan Stanley
- S&P 500, Dow end at record highs as weak jobs data eases rate worries
- U.S. Added Only 266,000 Jobs in April, Well Below Estimates
- Roku (ROKU) Surges After Crushing Profit Estimates to Prompt an Upgrade to 'Buy' at Loop Capital
- Dollar broadly weaker after U.S. jobs data disappoint
- Square (SQ) Tops Q1 EPS by 25c
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Morgan Stanley analyst Matthew Harrison reiterated an Equalweight rating and $45.00 price target on bluebird bio (NASDAQ: BLUE) after management provided an update indicating that it does not believe that Lentiglobin caused the AML case in the SCD trial for the following reasons:
1) Mgt. identified various mutations as well as key chromosomal abnormalities in this patient that have been associated with AML
2) Although Lentiglobin was found in the VAMP4 gene, the latter does not appear to be related with AML and
was not found to likely have impacted other genes in the vicinity or caused gene misregulation
The analyst stated "We agree with mgt. that lentiglobin does not appear to be the cause of the AML case and thus expect BLUE up on the news. That said, given unknowns around how regulators will view the case and what requirements they will have to resume the studies, some residual uncertainty remains."
Shares of bluebird bio closed at $33.15 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tilray (TLRY) Gets a Two-Notch Upgrade to 'Buy' at Jefferies as Aphria Merger is Seen as a 'Perfect Match'
- Genmab A/S (GEN:DC) (GMAB) PT Raised to DKK2,270 at Goldman Sachs
- Thales SA (HO:FP) (THLEF) PT Raised to EUR105 at Goldman Sachs
Create E-mail Alert Related CategoriesAnalyst Comments, Hot Comments
Related EntitiesMorgan Stanley
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!